Skip to main content
. Author manuscript; available in PMC: 2009 Apr 1.
Published in final edited form as: Am J Hypertens. 2008 Aug 28;21(10):1111–1116. doi: 10.1038/ajh.2008.248

Table 1.

Characteristics of atrial fibrillation cases and controls

Cases Controls p -value
Characteristics a n = 433 n = 889
Age, mean (SD), y 72 (9) 67 (10) §
Female (%) 232 (53.6) 380 (42.7) §
White race (%) 400 (93.0) 769 (87.4) < 0.01
Duration of GH enrollment, mean (SD), y 22 (12) 20 (12) 0.08
Body mass index, mean (SD), kg/m2 31 (8) 30 (6) 0.36
Alcohol (%) 0.10
  Never or former 180 (42.9) 319 (37.6)
  Occasional 179 (42.6) 414 (48.9)
  Heavy 61 (14.5) 114 (13.5)
Smoking (%) 0.22
  Never or former 403 (93.1) 810 (91.1)
  Current 30 (6.9) 79 (8.9)
Glomerular Filtration Rate (ml/min/1.73 m2) < 0.01
  Stage 1 (normal) ≥ 90 119 (27.6) 355 (40.2)
  Stage 2 (mild reduction) 60-89 165 (38.4) 319 (36.2)
  Stage 3 (moderate reduction) 30-59 127 (29.5) 191 (21.7)
  Stage 4 (severe reduction) 15-29 9 (2.1) 12 (1.4)
  Stage 5 (kidney failure) <15 10 (2.3) 5 (0.6)
Diabetes mellitus (%) 79 (18.2) 132 (14.9) 0.11
Myocardial infarction (%) 44 (10.2) 68 (7.7) 0.12
Stroke (%) 37 (8.6) 46 (5.2) 0.02
Hyperlipidemia (%) 99 (22.9) 215 (24.2) 0.60
Valvular heart disease (%) 18 (4.2) 24 (2.7) 0.16
Anti-hypertensive medication (%) b
  Thiazide or loop diuretic 183 (42.3) 321 (36.1) 0.03
  Potassium-sparing diuretic 55 (12.7) 91 (10.2) 0.18
  ACE inhibitor 132 (30.5) 345 (38.8) < 0.01
  Beta blocker 187 (43.2) 360 (40.5) 0.35
  Calcium channel blocker 52 (12.0) 108 (12.2) 0.94
  Other 16 (3.7) 27 (3.0) 0.53
Serum potassium, mean (SD), mEq/L 4.3 (0.5) 4.3 (0.5) 0.86
Duration of treated hypertension,
mean (SD), y
13 (9) 12 (10) 0.01
Average achieved systolic blood pressure,
mean (SD), mm Hg
144 (15) 140 (14) < 0.01 c
  <120 (%) 27 (6.2) 50 (5.6) < 0.01 d
  120-129 (%) 46 (10.6) 150 (16.9)
  130-139 (%) 91 (21.0) 237 (26.7)
  140-149 (%) 124 (28.6) 256 (28.8)
  150-159 (%) 88 (20.3) 124 (14.0)
  160-169 (%) 40 (9.2) 48 (5.4)
  ≥ 170 (%) 17 (3.9) 24 (2.7)
Average achieved diastolic blood pressure,
mean (SD), mm Hg
79 (10) 80 (9) 0.10 c
  <65 (%) 30 (6.9) 39 (4.4) 0.25 d
  65-69 (%) 40 (9.2) 71 (8.0)
  70-74 (%) 68 (15.7) 134 (15.1)
  75-79 (%) 90 (20.8) 189 (21.3)
  80-84 (%) 96 (22.2) 195 (22.9)
  85-89 (%) 60 (13.9) 162 (18.2)
  90-94 (%) 26 (6.0) 63 (7.1)
  ≥ 95 (%) 23 (5.3) 36 (4.1)
Average pre-treatment systolic blood
pressure, mean (SD), mm Hg
158 (16) 156 (15) 0.08 c
  <120 (%) 1 (0.3) 0 (0.0) 0.13 d
  120-129 (%) 5 (1.6) 6 (1.0)
  130-139 (%) 29 (9.1) 62 (9.7)
  140-149 (%) 61 (19.1) 165 (25.7)
  150-159 (%) 88 (27.6) 169 (26.4)
  160-169 (%) 67 (21.0) 134 (20.9)
  ≥170 (%) 68 (21.3) 105 (16.4)
Average pre-treatment diastolic blood
pressure, mean (SD), mm Hg
93 (9) 94 (9) 0.02 c
  <65 (%) 0 (0.0) 1 (0.2) 0.09 d
  65-69 (%) 2 (0.6) 3 (0.5)
  70-74 (%) 6 (1.9) 5 (0.8)
  75-79 (%) 18 (5.6) 19 (3.0)
  80-84 (%) 29 (9.1) 38 (5.9)
  85-89 (%) 48 (15.1) 115 (17.9)
  90-94 (%) 78 (24.5) 148 (23.1)
  ≥95 (%) 139 (43.3) 312 (48.7)
§

Cases and controls were frequency matched on age and sex

a

BMI was missing in 2 cases and 9 controls; alcohol use in 13 cases and 42 controls; race in 3 cases and 9 controls; duration of GH enrollment in 2 cases and 5 controls; glomerular filtration rate in 3 cases and 7 controls; potassium level in 6 cases and 13 controls; duration of hypertension in 65 cases and 146 controls; average pre-treatment systolic and diastolic blood pressure in 114 cases and 248 controls

b

Anti-hypertensive medication categories are not mutually exclusive; patients could be on more than one anti-hypertensive medication

c

P value given for a difference in blood pressure means

d

P value given for differences in blood pressure categories